Oneness Biotech receives a Korean patent on FB704A, an anti-IL6 fully-human antibody new drug.
· Issued by Oneness Biotech Co., Ltd.
Close
Today's Information
Provided by: ONENESS BIOTECH CO., LTD.
SEQ_NO
1
Date of announcement
2022/01/25
Time of announcement
18:21:21
Subject
Oneness Biotech Co., Ltd. receives a Korean patent on
FB704A, an anti-IL6 fully-human antibody new drug.
Date of events
2022/01/25
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/01/25
2.Company name:ONENESS BIOTECH CO., LTD.
3.Relationship to the Company (please enter ��head office�� or
��subsidiaries��):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:
The Company has been informed by the patent agency that the FB704A, an
anti-IL6 fully-human antibody new drug has been granted a Korean patent
titled ��ANTIBODIES TO INTERLEUKIN-6 AND USES THEREOF��under the patent number
10-2321372.
6.Countermeasures:None
7.Any other matters that need to be specified:None
